Triazolam: Side Effects, Uses & Monitoring
Facts extracted from current FDA product labeling for Triazolam. Educational only — not medical advice.
Reported adverse reactions
| Reaction | Highest frequency reported* |
|---|---|
| Drowsiness | 14% |
| Wbc/hpf | 11.7% |
| Eosinophil count | 10.2% |
| Headache | 9.7% |
| Dizziness | 7.8% |
| Sgot | 5.3% |
| Nervousness | 5.2% |
| Light-headedness | 4.9% |
| Coordination disorders/ataxia | 4.6% |
| Nausea/vomiting | 4.6% |
| Monocyte count | 4.4% |
| Lymphocyte count | 4% |
| Creatinine | 3.6% |
| Neutrophil count | 3.3% |
| Rbc/hpf | 2.9% |
| Alkaline phosphatase | 2.6% |
| Total wbc count | 2.1% |
| Basophil count | 2.1% |
| Bilirubin | 1.5% |
| Albumin | 1.1% |
*Highest percentage across placebo-controlled trial tables summarized in current labeling.
Labeled uses
Triazolam Tablets are indicated for the short-term treatment of insomnia (generally 7 to 10 days). Use for more than 2 to 3 weeks requires complete reevaluation of the patient (see WARNINGS ). Prescriptions for triazolam should be written for short-term use (7 to 10 days) and it should not be prescribed in quantities exceeding a 1-month supply.
Source: FDA labeling via NIH DailyMed (set 73db8a0e…). Not affiliated with FDA or NIH.
Medical disclaimer: Always consult a qualified healthcare professional about any medication.